Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 920
Filter
1.
Exp Cell Res ; 439(1): 114090, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38740167

ABSTRACT

Dopamine D2 receptors (D2Rs) play crucial roles in regulating diverse physiological functions of the central nervous system and peripheral organs. D2Rs are also expressed in mammary glands. However, which cell types express D2Rs and whether they are involved in milk production remains unclear. The present findings revealed that D2Rs are expressed in the apical regions of the lateral membranes of mammary epithelial cells (MECs) in lactating mice. We also investigated the effects of the D2R agonist bromocriptine and/or antagonist domperidone on intracellular cAMP levels, milk protein production, and apoptosis in a lactation culture model of MECs that produce major milk components like lactating MECs in vivo. We found that bromocriptine decreased intracellular cAMP levels, whereas domperidone dose-dependently neutralized this effect. Bromocriptine also inhibited casein and lactoferrin production and suppressed activities of STAT5 and glucocorticoid receptors (GRs). Domperidone neutralized the inhibition of casein production as well as STAT5 and GR inactivation induced by bromocriptine. Furthermore, D2R activation by bromocriptine induced apoptosis and inactivated ERK, a signaling molecule responsible for promoting cell proliferation and survival. Domperidone attenuated ERK inactivation and apoptosis induced by bromocriptine. These findings suggest that D2Rs play regulatory roles in milk protein production and apoptosis in MECs.


Subject(s)
Apoptosis , Bromocriptine , Domperidone , Epithelial Cells , Lactation , Mammary Glands, Animal , Milk Proteins , Receptors, Dopamine D2 , Animals , Female , Mice , Apoptosis/drug effects , Bromocriptine/pharmacology , Cells, Cultured , Cyclic AMP/metabolism , Domperidone/pharmacology , Epithelial Cells/metabolism , Epithelial Cells/drug effects , Lactation/metabolism , Mammary Glands, Animal/cytology , Mammary Glands, Animal/metabolism , Milk Proteins/metabolism , Milk Proteins/genetics , Receptors, Dopamine D2/metabolism , Receptors, Dopamine D2/genetics , STAT5 Transcription Factor/metabolism
2.
J Biol Chem ; 298(12): 102635, 2022 12.
Article in English | MEDLINE | ID: mdl-36273581

ABSTRACT

Cancer cells intrinsically proliferate in an autonomous manner; however, the expansion of cancer cell areas in a tissue is known to be regulated by surrounding nontransformed cells. Whether these nontransformed cells can be targeted to control the spread of cancer cells is not understood. In this study, we established a system to evaluate the cancer-inhibitory activity of surrounding nontransformed cells and screened chemical compounds that could induce this activity. Our findings revealed that lonidamine (LND) and domperidone (DPD) inhibited expansion of oncogenic foci of KRASG12D-expressing transformed cells, whereas they did not inhibit the proliferation of monocultured KRASG12D-expressing cells. Live imaging revealed that LND and DPD suppressed the movement of nontransformed cells away from the attaching cancer cells. Moreover, we determined that LND and DPD promoted stress fiber formation, and the dominant-negative mutant of a small GTPase RhoA relieved the suppression of focus expansion, suggesting that RhoA-mediated stress fiber formation is involved in the inhibition of the movement of nontransformed cells and focus expansion. In conclusion, we suggest that elucidation of the mechanism of action of LND and DPD may lead to the development of a new type of drug that could induce the anticancer activity of surrounding nontransformed cells.


Subject(s)
Antineoplastic Agents , Domperidone , Indazoles , Neoplasms , Domperidone/pharmacology , Indazoles/pharmacology , Antineoplastic Agents/pharmacology , Neoplasms/drug therapy , Neoplasms/pathology , Animals , Mice , Epithelial Cells , Mammary Glands, Animal/cytology , Drug Screening Assays, Antitumor
3.
BMC Genomics ; 24(1): 40, 2023 Jan 24.
Article in English | MEDLINE | ID: mdl-36694114

ABSTRACT

BACKGROUND: Gilts experiencing sustained hyperprolactinemia from d 90 to 109 of gestation showed an early onset of lactogenesis coupled with premature mammary involution. To better understand the molecular mechanisms underlying the premature mammary involution observed in these gilts, a transcriptomic analysis was undertaken. Therefore, this study aimed to explore the effect of hyperprolactinemia on the global transcriptome in the mammary tissue of late gestating gilts and identify the molecular pathways involved in triggering premature mammary involution. METHODS: On d 90 of gestation, gilts received daily injections of (1) canola oil until d 109 ± 1 of gestation (CTL, n = 18); (2) domperidone (to induce hyperprolactinemia) until d 96 ± 1 of gestation (T7, n = 17) or; (3) domperidone (until d 109 ± 1 of gestation (T20, n = 17). Mammary tissue was collected on d 110 of gestation and total RNA was isolated from six CTL and six T20 gilts for microarray analysis. The GeneChip® Porcine Gene 1.0 ST Array was used for hybridization. Functional enrichment analyses were performed to explore the biological significance of differentially expressed genes, using the DAVID bioinformatics resource. RESULTS: The expression of 335 genes was up-regulated and that of 505 genes down-regulated in the mammary tissue of T20 vs CTL gilts. Biological process GO terms and KEGG pathways enriched in T20 vs CTL gilts reflected the concurrent premature lactogenesis and mammary involution. When looking at individual genes, it appears that mammary cells from T20 gilts can simultaneously upregulate the transcription of milk proteins such as WAP, CSN1S2 and LALBA, and genes triggering mammary involution such as STAT3, OSMR and IL6R. The down-regulation of PRLR expression and up-regulation of genes known to inactivate the JAK-STAT5 pathway (CISH, PTPN6) suggest the presence of a negative feedback loop trying to counteract the effects of hyperprolactinemia. CONCLUSIONS: Genes and pathways identified in this study suggest that sustained hyperprolactinemia during late-pregnancy, in the absence of suckling piglets, sends conflicting pro-survival and cell death signals to mammary epithelial cells. Reception of these signals results in a mammary gland that can simultaneously synthesize milk proteins and initiate mammary involution.


Subject(s)
Hyperprolactinemia , Pregnancy , Swine , Animals , Female , Hyperprolactinemia/chemically induced , Hyperprolactinemia/genetics , Hyperprolactinemia/metabolism , Transcriptome , Domperidone/metabolism , Domperidone/pharmacology , Parenchymal Tissue , Mammary Glands, Animal/metabolism , Sus scrofa , Lactation
4.
J Pediatr Gastroenterol Nutr ; 77(2): e13-e22, 2023 08 01.
Article in English | MEDLINE | ID: mdl-37159421

ABSTRACT

Domperidone is a peripheral dopamine-2 receptor antagonist with prokinetic and antiemetic properties. Its prokinetic effects are mainly manifest in the upper gastrointestinal (GI) tract. Currently its use is restricted to relief of nausea and vomiting in children older than 12 years for a short period of time. However, among (pediatric) gastroenterologists, domperidone is also used outside its authorized indication ("off label") for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis. Little is known about its efficacy in the treatment of GI motility disorders in children and controversial data have emerged in the pediatric literature. As its use is off label, appropriate knowledge of its efficacy is helpful to support an "off label/on evidence" prescription. Based on this, the purpose of this review is to summarize all evidence on the efficacy of domperidone for the treatment of GI disorders in infants and children and to report an overview of its pharmacological properties and safety profile.


Subject(s)
Antiemetics , Gastrointestinal Diseases , Infant , Humans , Child , Domperidone/pharmacology , Domperidone/therapeutic use , Antiemetics/therapeutic use , Gastrointestinal Diseases/drug therapy , Gastrointestinal Agents/therapeutic use , Vomiting/drug therapy
5.
Proc Natl Acad Sci U S A ; 117(51): 32453-32463, 2020 12 22.
Article in English | MEDLINE | ID: mdl-33288711

ABSTRACT

Pathogenic mutations in the copper transporter ATP7B have been hypothesized to affect its protein interaction landscape contributing to loss of function and, thereby, to hepatic copper toxicosis in Wilson disease. Although targeting mutant interactomes was proposed as a therapeutic strategy, druggable interactors for rescue of ATP7B mutants remain elusive. Using proteomics, we found that the frequent H1069Q substitution promotes ATP7B interaction with HSP70, thus accelerating endoplasmic reticulum (ER) degradation of the mutant protein and consequent copper accumulation in hepatic cells. This prompted us to use an HSP70 inhibitor as bait in a bioinformatics search for structurally similar Food and Drug Administration-approved drugs. Among the hits, domperidone emerged as an effective corrector that recovered trafficking and function of ATP7B-H1069Q by impairing its exposure to the HSP70 proteostatic network. Our findings suggest that HSP70-mediated degradation can be safely targeted with domperidone to rescue ER-retained ATP7B mutants and, hence, to counter the onset of Wilson disease.


Subject(s)
Copper-Transporting ATPases/genetics , Copper-Transporting ATPases/metabolism , Domperidone/pharmacology , HSP70 Heat-Shock Proteins/metabolism , Hepatolenticular Degeneration/genetics , Benzimidazoles/chemistry , Benzimidazoles/pharmacology , Cells, Cultured , Copper/metabolism , Domperidone/chemistry , Endoplasmic Reticulum/drug effects , Endoplasmic Reticulum/metabolism , HSP70 Heat-Shock Proteins/antagonists & inhibitors , Hep G2 Cells , Hepatocytes/metabolism , Hepatolenticular Degeneration/drug therapy , Hepatolenticular Degeneration/metabolism , Hepatolenticular Degeneration/pathology , Humans , Mutation, Missense , Nipecotic Acids/chemistry , Nipecotic Acids/pharmacology , Protein Transport/drug effects , Protein Transport/genetics , Proteomics/methods
6.
Int J Mol Sci ; 24(4)2023 Feb 17.
Article in English | MEDLINE | ID: mdl-36835497

ABSTRACT

Several theories have been proposed to explain the mechanisms of substance use in schizophrenia. Brain neurons pose a potential to provide novel insights into the association between opioid addiction, withdrawal, and schizophrenia. Thus, we exposed zebrafish larvae at 2 days post-fertilization (dpf) to domperidone (DPM) and morphine, followed by morphine withdrawal. Drug-induced locomotion and social preference were assessed, while the level of dopamine and the number of dopaminergic neurons were quantified. In the brain tissue, the expression levels of genes associated with schizophrenia were measured. The effects of DMP and morphine were compared to vehicle control and MK-801, a positive control to mimic schizophrenia. Gene expression analysis revealed that α1C, α1Sa, α1Aa, drd2a, and th1 were up-regulated after 10 days of exposure to DMP and morphine, while th2 was down-regulated. These two drugs also increased the number of positive dopaminergic neurons and the total dopamine level but reduced the locomotion and social preference. The termination of morphine exposure led to the up-regulation of th2, drd2a, and c-fos during the withdrawal phase. Our integrated data implicate that the dopamine system plays a key role in the deficits in social behavior and locomotion that are common in the schizophrenia-like symptoms and opioid dependence.


Subject(s)
Calcium Channels , Domperidone , Dopamine Antagonists , Dopamine , Dopaminergic Neurons , Morphine , Opioid-Related Disorders , Schizophrenia , Animals , Calcium Channels/metabolism , Dopamine/metabolism , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/metabolism , Morphine/administration & dosage , Morphine/pharmacology , Opioid-Related Disorders/metabolism , Schizophrenia/metabolism , Zebrafish , Domperidone/administration & dosage , Domperidone/pharmacology , Dopamine Antagonists/administration & dosage , Dopamine Antagonists/pharmacology , Locomotion/drug effects , Metabolic Networks and Pathways
7.
J Gen Virol ; 103(6)2022 06.
Article in English | MEDLINE | ID: mdl-35731650

ABSTRACT

Oncolytic adenoviruses (OAds) have attracted much attention as novel anticancer agents. Numerous studies have examined the antitumour effects of combinational use of an OAd and anticancer agents; however, few chemical compounds enhancing OAd infection have been reported. In this study, we screened a food and drug administration (FDA)-approved drug library containing 1134 small chemical compounds to identify chemical compounds that enhance OAd replication in human tumour cells. We found that domperidone, a dopamine D2 receptor antagonist, significantly enhanced the replication of an OAd in human tumour cells, including human pancreatic tumour cells, by two-fivefold, resulting in improvement of OAd-mediated tumour cell killing activities. The E1A mRNA levels were significantly increased in domperidone-pre-treated cells following OAd infection, which contributed to the promotion of OAd replication. However, mRNA levels of the dopamine D2 receptor (DRD2), which is known to be a target molecule of domperidone, were undetectable in most of the tumour cells by real-time reverse transcription (RT)-PCR analysis, indicating that domperidone promoted OAd replication by acting on a molecule other than DRD2. This study provides important clues for the improvement of OAd-mediated cancer therapy.


Subject(s)
Adenoviridae Infections , Antineoplastic Agents , Oncolytic Virotherapy , Oncolytic Viruses , Adenoviridae/genetics , Cell Line, Tumor , Domperidone/pharmacology , Dopamine Antagonists/pharmacology , Humans , Oncolytic Virotherapy/methods , Oncolytic Viruses/genetics , RNA, Messenger/genetics
8.
Alcohol Clin Exp Res ; 46(3): 396-409, 2022 03.
Article in English | MEDLINE | ID: mdl-35040146

ABSTRACT

BACKGROUND: Dopamine neuron firing in the ventral tegmental area (VTA) and dopamine release in the nucleus accumbens have been implicated in reward learning. Ethanol is known to increase both dopamine neuron firing in the VTA and dopamine levels in the nucleus accumbens. Despite this, some discrepancies exist between the dose of ethanol required to enhance firing in vivo and ex vivo. In the present study we investigated the effects of peripheral dopamine 2 subtype receptor antagonism on ethanol's effects on dopamine neurotransmission. METHODS: Plasma catecholamine levels were assessed following ethanol administration across four different doses of EtOH. Microdialysis and voltammetry were used to assess the effects of domperidone pretreatment on ethanol-mediated increases in dopamine release in the nucleus accumbens. A place conditioning paradigm was used to assess conditioned preference for ethanol and whether domperidone pretreatment altered this preference. Open-field and loss-of-righting reflex paradigms were used to assess the effects of domperidone on ethanol-induced sedation. A rotarod apparatus was used to assess the effects of domperidone on ethanol-induced motor impairment. RESULTS: Domperidone attenuated ethanol's enhancement of mesolimbic dopamine release under non-physiological conditions at intermediate (1.0 and 2.0 g/kg) doses of ethanol. Domperidone also decreased EtOH-induced sedation at 2.0 g/kg. Domperidone did not alter ethanol conditioned place preference nor did it affect ethanol-induced motor impairment. CONCLUSIONS: These results show that peripheral dopamine 2 receptors mediate some of the effects of ethanol on nonphysiological dopamine neurotransmission, although these effects are not related to the rewarding properties of ethanol.


Subject(s)
Dopamine , Nucleus Accumbens , Domperidone/pharmacology , Ethanol/pharmacology , Ventral Tegmental Area
9.
J Pharmacol Exp Ther ; 379(1): 85-95, 2021 10.
Article in English | MEDLINE | ID: mdl-34253646

ABSTRACT

Current therapies for gastroparesis metoclopramide and domperidone carry risks of extrapyramidal symptoms and life-threatening cardiac arrhythmias. Trazpiroben, a novel, potent dopamine D2/D3 receptor antagonist, has low brain permeation and very low affinity for human ether-à-go-go-related gene (hERG) channel inhibition, potentially improving on safety profiles of existing therapies. Trazpiroben demonstrated the following receptor affinities: high for D2 and D3, moderate for D4, and minimal for D1 and D5 It demonstrated moderate affinity for adrenergic α 1B (α 1B) and 5-hydroxytryptamine (5HT) 2A receptors and low potential for off-target adverse events (AEs). Trazpiroben potently inhibited dopamine-activated D2L receptor activation of cognate G-proteins in human embryonic kidney 293 cell membranes and was a neutral D2L receptor antagonist. In vivo, trazpiroben dose-dependently increased prolactin release in orally dosed rat (0.1-1 mg/kg). Additionally, multiple oral doses in the rat (100 mg/kg) and dog (50 mg/kg) for 3 days produced robust plasma exposures and prolactin increases in both species. Trazpiroben inhibited retching/vomiting in the dog with apomorphine-induced emesis with a potency (0.1-1 mg/kg) like that of trazpiroben-mediated prolactin increases in rat. Oral trazpiroben (1, 10, and 30 mg/kg) did not affect rat rotarod performance, suggesting low brain penetration. Trazpiroben concentrations were low in cerebrospinal fluid versus plasma after multiple oral doses for 4 days in rat and dog. Trazpiroben weakly inhibited the hERG channel current (concentration causing half-maximal inhibition of control-specific binding of 15.6 µM), indicating little potential for disrupting cardiac rhythm. Overall, trazpiroben is a potent D2/D3 receptor antagonist designed to avoid the serious potential AEs associated with current gastroparesis therapies. SIGNIFICANCE STATEMENT: Trazpiroben is a novel, potent dopamine D2/D3 selective receptor antagonist designed to avoid adverse effects associated with the current pharmacological therapies metoclopramide and domperidone. Preclinical studies have demonstrated low brain penetration and weak affinity for the hERG channel, indicating that trazpiroben is not expected to be associated with central nervous system or cardiovascular safety issues. With these pharmacological properties, trazpiroben may represent a viable new treatment option for gastroparesis because of a potentially improved safety profile relative to existing therapies.


Subject(s)
Dopamine D2 Receptor Antagonists/therapeutic use , Gastroparesis/drug therapy , Receptors, Dopamine D3/antagonists & inhibitors , Triazoles/therapeutic use , Animals , Antiemetics/pharmacology , Antiemetics/therapeutic use , CHO Cells , Cricetinae , Cricetulus , Dogs , Domperidone/analogs & derivatives , Domperidone/pharmacology , Domperidone/therapeutic use , Dopamine Antagonists/chemistry , Dopamine Antagonists/pharmacology , Dopamine Antagonists/therapeutic use , Dopamine D2 Receptor Antagonists/chemistry , Dopamine D2 Receptor Antagonists/pharmacology , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , Female , HEK293 Cells , Humans , Male , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D2/metabolism , Receptors, Dopamine D3/metabolism , Triazoles/pharmacology
10.
Cell Commun Signal ; 19(1): 43, 2021 04 08.
Article in English | MEDLINE | ID: mdl-33832505

ABSTRACT

BACKGROUND: Phosphotyrosine kinase (PTK)-mediated phospholipase C-γ1 (PLC-γ1) signaling plays a crucial role in the release of the universal second messenger calcium from intracellular stores, which is mandatory for several cellular processes, including cell migration. However, PLC-γ1 could also be activated in a PTK-independent manner by phospholipase D (PLD)-derived phosphatidic acid (PA). Because both higher PLD expression levels and PLD activity have also been associated with breast cancer cell invasion and migration, we wondered whether there might be a link between PLD and PLC-γ1, which was investigated in this study. MATERIALS: MDA-MB-468-NEO (EGFR positive) and MDA-MB-468-HER2 (EGFR and HER2 positive) human breast cancer cells were used in this study. The migratory behavior of the cells in the presence of epidermal growth factor (EGF) and the PLD inhibitor 5-fluoro-2-indolyl-des-chlorohalopemide (FIPI) was analyzed using the 3D collagen matrix migration assay. Changes in cytosolic calcium levels in the presence of EGF, FIPI and Sig-1R agonists and antagonists as well as in PLD1 siRNA knockdown cells were determined by flow cytometry. Western blot analyses were performed to determine the basal expression levels and phosphorylation patterns of EGFR, HER2, AKT, MAPKp42/44, PLC-γ1 and Sig-1R. RESULTS: The EGF-induced migration of MDA-MB-468-NEO and MDA-MB-468-HER2 cells was significantly impaired by FIPI. Likewise, FIPI also significantly abolished EGF-induced calcium release in both cell lines. However, neither the expression levels nor the phosphorylation patterns of EGFR, HER2, AKT, MAPKp42/44 and PLC-γ1 were markedly changed by FIPI. Knockdown of PLD1 expression by siRNA also significantly impaired EGF-induced calcium release in both cell lines. Targeting Sig-1R, which interacts with IP3R, with the antagonist BD1047 also abrogated EGF-induced calcium release. However, EGF-induced calcium release was also impaired if cells were treated with the Sig-1R agonists PRE084 and PPBP maleate. CONCLUSION: In summary, blocking PLD activity with the specific inhibitor FIPI or knocking down PDL1 expression by siRNA significantly impaired EGF-induced calcium release in MDA-MB-468-NEO and MDA-MB-468-HER2 cells, likely indicating a connection between PLD activity and PLC-γ1-mediated calcium signaling. However, how PLD activity interferes with the release of calcium from intracellular stores remains unclear. Video Abstract.


Subject(s)
Breast Neoplasms/metabolism , Calcium Signaling , Domperidone/analogs & derivatives , Enzyme Inhibitors/pharmacology , Epidermal Growth Factor/pharmacology , Indoles/pharmacology , Phospholipase D/antagonists & inhibitors , Breast Neoplasms/pathology , Calcium/metabolism , Calcium Signaling/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Domperidone/pharmacology , ErbB Receptors/metabolism , Female , Humans , Phospholipase D/metabolism , Phosphorylation/drug effects , RNA, Small Interfering/metabolism , Receptors, sigma/metabolism , Sigma-1 Receptor
11.
Curr Microbiol ; 78(11): 3957-3967, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34550434

ABSTRACT

Candida albicans is the most common human fungal pathogen that has developed extensive virulence factors which allows successful colonization and infection of the host. Anti-virulence agents can alleviate the pathogenesis of fungi and help the immune system to eradicate them easily. This study aimed to explore the anti-virulence effect of domperidone and candesartan against C. albicans standard strain. Sub-inhibitory concentrations (1/4 and 1/8 of minimum inhibitory concentration) of domperidone and candesartan significantly inhibited the virulence factors hemolysin, lipase, protease, phospholipase, and bioflim formation. It was found that candesartan inhibited biofilm formation by 60.48-67.91%, hemolysin activity (61.21-74.14%), phospholipase activity (40-49.67%), lipase activity (58.97-73%), and protease activity (52.63%), while domperidone was found to inhibit biofilm formation by 70.54-77.49%, hemolysin activity (64.84-69.84%), phospholipase activity (49.67-60%), lipase activity (50-54.87%), and protease activity (52.63-57.9%). Quantitative real time-PCR confirmed the anti-virulence activity of domperidone and candesartan as both drugs significantly reduce the expression of the virulence genes SAP2, SAP6, PLB1, PLB2, LIP4, LIP5. In conclusion, domperidone and candesartan could serve as anti-virulence agents for treatment of C. albicans infections.


Subject(s)
Candida albicans , Domperidone , Benzimidazoles , Biphenyl Compounds , Domperidone/pharmacology , Humans , Tetrazoles/pharmacology , Virulence
12.
Reprod Domest Anim ; 56(10): 1349-1357, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34342069

ABSTRACT

Kisspeptin, upstream of the hypothalamic-pituitary-gonadal axis, play an essential role in the reproductive process. In the present study, the effect of different types of kisspeptin, including goldfish (Carassius auratus) kiss1 kisspeptin (Kiss1), human kisspeptin (Hkiss) and their combination (Kiss1+H) on the reproductive-related genes (kiss1, Kissr and Cyp19) of adult female goldfish was investigated in comparison with Ovaprim (a synthetic GnRH hormone). Kiss1 and Hkiss were synthesized using a solid-phase synthesis approach. Peptides were injected at a dose of 100 µg/kg body weight. The brain and ovarian tissues of samples were separated for histological studies 24 hr post-injection. The expression of the kiss1, Kissr and Cyp19 genes was measured by RT-PCR. The results showed a significant increase in expression of the reproductive-related genes. Histological analysis revealed higher number of mature oocytes in kisspeptin treated groups compare to other ones. In conclusion, Hkiss and Kiss1+H are the most effective peptides in oocyte maturation and expression of reproductive-related genes. In addition, it seems that kisspeptins in other domestic animals can be used to stimulate the hypothalamus-pituitary-gonadal axis.


Subject(s)
Goldfish/physiology , Kisspeptins/pharmacology , Oocytes/drug effects , Animals , Aromatase/genetics , Brain/metabolism , Domperidone/pharmacology , Drug Combinations , Female , Gene Expression/drug effects , Goldfish/genetics , Goldfish/metabolism , Gonadotropin-Releasing Hormone/pharmacology , Ovary/metabolism
13.
J Fish Biol ; 98(4): 1137-1143, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33314092

ABSTRACT

Despite several studies on fish hormone therapy, finding new candidates may provide more reproductive efficiency in artificial propagation. Kisspeptins, being upstream of the hypothalamic-pituitary-gonadal axis, appear to play a key role in the reproduction process. In the present study, the effect of different variants of kisspeptide, including goldfish (Carassius auratus) kiss1 kisspeptin (Kiss1), human kisspeptin (Hkiss), and their combination (Kiss1 + H), on the reproductive indices of goldfish broodstock in comparison to Ovaprim (a typical synthetic Gnrh hormone) was investigated. Peptides (Kiss1 and Hkiss) were synthesized using a solid-phase synthesis approach. Kiss1 and Hkiss were injected at a dose of 100 µg kg-1 body weight, blood samples were taken 6 h after injection and sex hormones (E2, Dhp, and 11-Kt), gonadotropins (Lh and Fsh), cortisol and reproductive indices (fecundity, fertilization and hatching percentage) were measured. The results showed a significant increase of plasma sex hormones and gonadotropins in fish treated with kisspeptins. In addition, the cortisol and lipoprotein lipase in Kiss1, Hkiss and Kiss1 + H were remarkably increased compared to Ovaprim. In conclusion, kisspeptins could be a more suitable candidate than Ovaprim for accelerating and synchronizing oocyte maturation in the fisheries industry.


Subject(s)
Goldfish/physiology , Kisspeptins/pharmacology , Reproduction/drug effects , Animals , Domperidone/administration & dosage , Domperidone/pharmacology , Drug Combinations , Estradiol/blood , Estradiol/metabolism , Female , Follicle Stimulating Hormone/blood , Follicle Stimulating Hormone/metabolism , Gonadotropin-Releasing Hormone/administration & dosage , Gonadotropin-Releasing Hormone/pharmacology , Humans , Hydrocortisone/blood , Hydrocortisone/metabolism , Luteinizing Hormone/blood , Luteinizing Hormone/metabolism , Male , Progesterone/blood , Progesterone/metabolism , Reproduction/physiology , Testosterone/blood , Testosterone/metabolism
14.
Ter Arkh ; 93(8): 982-985, 2021 Aug 15.
Article in Russian | MEDLINE | ID: mdl-36286896

ABSTRACT

Functional dyspepsia is one of the most common functional disorders of the gastrointestinal tract, which resulted from impaired motor skills, visceral hypersensitivity, increased mucosal permeability, disorders of the autonomic nervous system, etc. There is no specific therapy for this disease, which often leads to the irrational use of various groups of drugs. Drug therapy is recommended only during periods of symptoms. The main options of pharmacotherapy include the use of proton pump inhibitors, phytotherapeutic drugs, eradication therapy of Helicobacter pylori. Against the background of possible motor disorders, prokinetics are also one of the possible treatment options, but cisapride has long been withdrawn from sale due to cardiotoxicity, the use of domperidone and metoclopramide is limited due to side effects, especially with long-term therapy, so currently the only prokinetic that can be used in everyday clinical practice is itopride. In refractory cases, tricyclic antidepressants and psychotherapeutic approaches are another effective treatment option.


Subject(s)
Dyspepsia , Helicobacter Infections , Humans , Dyspepsia/diagnosis , Dyspepsia/drug therapy , Dyspepsia/etiology , Cisapride/therapeutic use , Domperidone/pharmacology , Domperidone/therapeutic use , Proton Pump Inhibitors/therapeutic use , Metoclopramide/therapeutic use , Antidepressive Agents, Tricyclic/therapeutic use , Helicobacter Infections/drug therapy
15.
Gastroenterology ; 156(6): 1650-1660, 2019 05.
Article in English | MEDLINE | ID: mdl-30711628

ABSTRACT

BACKGROUND & AIMS: Studies have reported a lack of association between improvements in gastric emptying (GE) and upper gastrointestinal (UGI) symptoms with promotility drugs. However, GE test methods were suboptimal in some studies. We assessed improvements in GE and UGI symptoms in patients given promotility agents in studies with optimal or moderate test methods (scintigraphy or breath test, solid meal, >2 hours duration) compared to studies with suboptimal GE test methods. METHODS: With an expert librarian, we completed an extensive search of publications in the Ovid MEDLINE (1946 to present), EMBASE (1988 to January 2018), and EBM Reviews Cochrane Central Register of Controlled Trials, without restrictions on language or year. Two independent reviewers evaluated the following inclusion criteria: randomized, blinded, parallel, or crossover trials of 5HT4 agonists, D2 receptor antagonist, or ghrelin agonists; trials that measured change in GE (T1/2) or composite UGI symptoms; trials of patients with functional dyspepsia and gastroparesis; and trials of GE test methods. Standardized mean differences (units expressed as SD) were used to standardize symptom assessments that were not uniform across studies. Random effects model was used to analyze data and meta-regression was used to evaluate the association between change in GE and UGI symptoms. RESULTS: Of 899 studies considered, 22 studies assessed change in GE; 23 evaluated UGI symptoms; and 14 evaluated GE and UGI symptoms. Promotility agents significantly accelerated GE (T1/2) in all studies (mean reduction in T1/2, 16.3 minutes; 95% confidence interval, -22.1 to -10.6 minutes) and in studies that used optimal GE test methods (mean reduction in T1/2, 23.6 minutes; 95% confidence interval, -32.3 to -14.9 minutes). Promotility agents also significantly reduced UGI symptoms (mean reduction, 0.25 SD; 95% confidence interval, -0.37 to -0.13 SD). Meta-regression found no significant association between change in GE and UGI symptoms. However, when only studies with optimal GE test methods were evaluated, there was a significant positive association between improvement in GE and UGI symptoms (P = .02). CONCLUSIONS: In a meta-analysis of published trials, we found promotility agents to significantly accelerate GE (when optimal test methods were used) and to produce significant improvements in UGI symptoms.


Subject(s)
Dopamine D2 Receptor Antagonists/pharmacology , Gastric Emptying/drug effects , Ghrelin/agonists , Serotonin 5-HT4 Receptor Agonists/pharmacology , Breath Tests , Cisapride/pharmacology , Domperidone/pharmacology , Dopamine D2 Receptor Antagonists/therapeutic use , Dyspepsia/drug therapy , Gastroparesis/drug therapy , Ghrelin/pharmacology , Humans , Macrocyclic Compounds/pharmacology , Oligopeptides/pharmacology , Radionuclide Imaging , Randomized Controlled Trials as Topic , Serotonin 5-HT4 Receptor Agonists/therapeutic use , Symptom Assessment
16.
Mol Reprod Dev ; 87(1): 124-134, 2020 01.
Article in English | MEDLINE | ID: mdl-31746511

ABSTRACT

Highly differentiated mature spermatozoa carry not only genetic but also epigenetic information that is to be transmitted to the embryo. DNA methylation is one epigenetic actor associated with sperm nucleus compaction, gene silencing, and prepatterning of embryonic gene expression. Therefore, the stability of this mark toward reproductive biotechnologies is a major issue in animal production. The present work explored the impact of hormonal induction of spermiation and sperm cryopreservation in two cyprinids, the goldfish (Carassius auratus) and the zebrafish (Danio rerio), using LUminometric Methylation Assay (LUMA). We showed that while goldfish hormonal treatment did increase sperm production, it did not alter global DNA methylation of spermatozoa. Different sperm samples repeatedly collected from the same males for 2 months also showed the same global DNA methylation level. Similarly, global DNA methylation was not affected after cryopreservation of goldfish spermatozoa with methanol, whereas less efficient cryoprotectants (dimethylsulfoxide and 1,2-propanediol) decreased DNA methylation. In contrast, cryopreservation of zebrafish spermatozoa with methanol induced a slight, but significant, increase in global DNA methylation. In the less compact nuclei, that is, goldfish fin somatic cells, cryopreservation did not change global DNA methylation regardless of the choice of cryoprotectant. To conclude, global DNA methylation is a robust parameter with respect to biotechnologies such as hormonal induction of spermiation and sperm cryopreservation, but it can be altered when the best sperm manipulation conditions are not met.


Subject(s)
Cryopreservation/methods , DNA Methylation/drug effects , Domperidone/pharmacology , Goldfish/genetics , Gonadotropin-Releasing Hormone/pharmacology , Semen Preservation/methods , Spermatozoa , Zebrafish/genetics , Animals , Cryoprotective Agents/pharmacology , Dimethyl Sulfoxide/pharmacology , Drug Combinations , Female , Fertilization in Vitro/methods , Male , Methanol/pharmacology , Oocytes , Propylene Glycol/pharmacology , Sperm Motility/drug effects
17.
Int J Clin Pharmacol Ther ; 58(12): 687-695, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32831161

ABSTRACT

OBJECTIVE: In 2014, the Korean Ministry of Food and Drug Safety (MFDS) issued a safety warning to carefully consider adverse cardiac effects when prescribing domperidone for children. We conducted this study to compare the trends of domperidone prescription in pediatrics before and after the MFDS safety warning. MATERIALS: This study included patients < 18 years old who used national health insurance services within the year 2011 and the year 2016, sampled from Health Insurance Review Agency data. METHODS: We analyzed domperidone prescribing patterns including prescribed daily dosage, maximum period of continuous prescription, and number and types of co-prescribed medications and compared two different years pre and post safety warning. RESULTS: A total of 16,614 pediatric patients (1.74%) received domperidone prescriptions in 2011, and 11,317 patients (1.23%) in 2016. The probability of receiving at least one prescription in 2016 has been reduced by 30% compared to 2011. Gastritis was the most common indication in both years. The number of prescriptions containing a maximum daily dosage of over 30 mg was significantly lower in 2016. In the same time period, the number of cases with a maximum continuous prescription period of more than 7 days significantly decreased (p < 0.001). In addition, from 2011 to 2016, comorbid diseases of domperidone-treated patients were similar, but the number of co-prescriptions of interacting medication to domperidone decreased (p < 0.001). CONCLUSION: After the 2014 safety letter was released, the pattern of prescribing domperidone in pediatrics has enhanced drug safety for children in terms of frequency of prescriptions, maximum duration of domperidone use, and the prescription of drugs interacting with domperidone.


Subject(s)
Domperidone/pharmacology , Drug-Related Side Effects and Adverse Reactions , Pediatrics , Adolescent , Child , Domperidone/adverse effects , Drug Prescriptions , Humans , Practice Patterns, Physicians' , Prescriptions , Republic of Korea
18.
J Fish Biol ; 96(1): 37-48, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31648360

ABSTRACT

The aim of this study was to determine the effect of stress on reproduction and the possible involvement of dopaminergic systems in the reproductive stress response in the mosquitofish Gambusia affinis. Exposure of fish to aquaculture stressors (four 10 min episodes of stress, each corresponding to a different stressor such as handling, chasing, frequent netting and low water levels), for a period of 30 days caused reduction in the mean numbers of stage I-IV follicles associated with lower number of pregnant females and embryos in most of the developmental stages compared with experimental controls. Besides, increase in the intensity of labelling and the per cent area of tyrosine hydroxylase (TH; a rate-limiting enzyme in the biosynthetic pathway of catecholamines)- immunoreactive (ir) neurons was observed in the preoptic area (POA) and the nucleus preopticus (NPO) regions of the brain concomitant with reduction in the labelling of gonadotropin releasing hormone-immunoreactive (GnRH-ir) fibres in the proximal pars distalis (PPD) of the pituitary gland in stressed fish compared with experimental controls. Treatment of domperidone (DOM) caused an increase in the number of stage II and V follicles and promoted pregnancy rate concomitant with an increase in the number of embryos at various developmental stages compared with those of experimental controls. Similar treatment to stressed fish caused an increase in the number of stages I-V follicles compared with those in stress alone group. The GnRH fibres showed increased immunolabelling in stress + DOM treated fish compared with stress alone fish. On the other hand, TH-immunoreactivity in the POA and the NPO regions was reduced in stress + DOM treated fish compared with stress-alone group. These results suggest that stress inhibits follicular development and subsequent hatching success through the suppression of GnRH and that the inhibition appears to be mediated through dopamine, for the first time in a viviparous fish.


Subject(s)
Cyprinodontiformes , Domperidone/pharmacology , Ovoviviparity , Reproduction/drug effects , Stress, Physiological/drug effects , Animals , Female , Gonadotropin-Releasing Hormone , Reproduction/physiology
19.
J Gastroenterol Hepatol ; 34(1): 186-193, 2019 Jan.
Article in English | MEDLINE | ID: mdl-29966173

ABSTRACT

BACKGROUND AND AIM: Metformin has been shown to have anti-cytokine property. Lipopolysaccharide (LPS)-induced or repeated water avoidance stress (WAS)-induced visceral allodynia and increased gut permeability were pro-inflammatory cytokine-dependent responses, which were considered to be animal models of irritable bowel syndrome (IBS). We hypothesized that metformin improves symptoms in the patients with IBS by attenuating these visceral changes and tested the hypothesis in rats. METHODS: The threshold of the visceromotor response induced by colonic balloon distention was measured. Colonic permeability was determined in vivo by quantifying the absorbed Evans blue for 15 min spectrophotometrically. RESULTS: Subcutaneously injected LPS (1 mg/kg) reduced the threshold of visceromotor response, and metformin (5-50 mg/kg for 3 days) intraperitoneally attenuated this response in a dose-dependent manner. Repeated WAS (1 h daily for 3 days) induced visceral allodynia, which was also blocked by metformin. The antinociceptive effect of metformin on the LPS-induced allodynia was reversed by compound C, an adenosine monophosphate-activated protein kinase inhibitor or NG -nitro-L-arginine methyl ester, a nitric oxide synthesis inhibitor but not modified by naloxone. Additionally, it was blocked by sulpiride, a dopamine D2 receptor antagonist, but domperidone, a peripheral dopamine D2 receptor antagonist, did not alter it. Metformin also blocked the LPS-induced or repeated WAS-induced increased colonic permeability. CONCLUSIONS: Metformin attenuated the visceral allodynia and increased gut permeability in animal IBS models. These actions may be evoked via activation of adenosine monophosphate-activated protein kinase, nitric oxide, and central dopamine D2 pathways. These results indicate the possibility that metformin can be useful for treating IBS.


Subject(s)
Evans Blue/metabolism , Hyperalgesia/prevention & control , Hypoglycemic Agents/therapeutic use , Intestinal Mucosa/metabolism , Irritable Bowel Syndrome/physiopathology , Metformin/therapeutic use , AMP-Activated Protein Kinases/antagonists & inhibitors , Animals , Colon/metabolism , Disease Models, Animal , Domperidone/pharmacology , Dopamine Antagonists/pharmacology , Hyperalgesia/etiology , Hypoglycemic Agents/pharmacology , Irritable Bowel Syndrome/chemically induced , Lipopolysaccharides , Male , Metformin/pharmacology , NG-Nitroarginine Methyl Ester/pharmacology , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Nociception/drug effects , Permeability/drug effects , Protein Kinase Inhibitors/pharmacology , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Rats , Rats, Sprague-Dawley , Stress, Physiological , Sulpiride/pharmacology
20.
Appl Microbiol Biotechnol ; 103(15): 6309-6318, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31209525

ABSTRACT

The number of infections caused by multidrug antibiotic resistance (MDR) species is increasing globally. The efflux pump system, AcrAB-TolC, confers Escherichia coli resistance to many antibiotics and results in poor treatment outcomes. Different rational drug design techniques were employed to search for a safe and effective AcrAB-TolC system inhibitor. Ligand docking was performed to analyze the binding of different ArcB substrates and/or inhibitors in the different AcrAB crystal structure binding sites. The validated docking site using the established docking preferences was used to perform virtual high-throughput screening on a large library of compounds. Domperidone, a known and safe over-the-counter antiemetic drug, was proposed as an effective ArcB inhibitor. Microbiological studies confirmed the computational results and domperidone reversed the resistance to the antibiotics: levofloxacin and ciprofloxacin in the MDR E. coli stains with an effect that surpassed the effect of the known efflux pump inhibitor, reserpine. In addition, it was able to increase both antibiotic effects on susceptible strains. This finding suggests that the antibiotic-domperidone combination can be used clinically to treat infections caused by multidrug-resistant E. coli strains.


Subject(s)
Biological Transport, Active/drug effects , Carrier Proteins/antagonists & inhibitors , Domperidone/isolation & purification , Drug Resistance, Multiple, Bacterial/drug effects , Enzyme Inhibitors/isolation & purification , Escherichia coli Proteins/antagonists & inhibitors , Escherichia coli/drug effects , Molecular Docking Simulation , Anti-Bacterial Agents/pharmacology , Domperidone/pharmacology , Drug Discovery/methods , Drug Synergism , Enzyme Inhibitors/pharmacology , Escherichia coli/enzymology
SELECTION OF CITATIONS
SEARCH DETAIL